Update and clinical highlights presented at the 2017American Society of Hematology Meeting

Update and clinical highlights presented at the 2017American Society of Hematology Meeting editorial memo (2018) 11:84 https://doi.org/10.1007/s12254-018-0417-x Update and clinical highlights presented at the 2017 American Society of Hematology Meeting Daniel Heintel Received: 2 May 2018 / Accepted: 22 May 2018 / Published online: 1 June 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 At the 2017 American Society of Hematology (ASH) rituximab maintenance following R-CHOP induction. meeting partly standards-changing data in the treat- The median PFS was 10.5 vs. 4 years (p < 0.0001). ment of hematological malignancies were presented. Also in mantle cell lymphoma, the superiority of More than 5000 scientific abstracts are submitted each rituximab maintenance was proven. year and more than 3000 abstracts are accepted for In fit patients with multiple myeloma, eligible for oral and poster presentations through an extensive autologous stem cell transplantation, new induction peer review process. In this issue of memo five hema- regimens showed high minimal residual disease neg- tologists summarized their personal highlights in their ativity rates. respective areas of expertise. Regarding CML interesting data regarding novel My personal highlight was the presentation of the TKIs or treatment duration of imatinib were pre- MURANO study. The clear superiority of a targeted sented. therapy changes practical behavior with immune- In the treatment of AML novel promising sub- chemotherapy having no place in second-line treat- stances enrich the spectrum of therapy choices which ment of chronic lymphocytic leukemia (CLL) any- also impressed the audience at the last ASH meeting. more. Moreover, the authors summarize important Conflict of interest D. Heintel receives honoraria from Abb- data about the combination of venetoclax and ibruti- vie, Celgene, Gilead, Janssen, MSD, Roche, Takeda. nib. In addition to CLL, reviews about important de- velopments in the treatment of indolent lymphoma, 7 For latest news from interna- multiple myeloma, CML, and AML are provided in this tional oncology congresses see: series. http://www.springermedizin.at/ Concerning indolent lymphoma, Dr. Gilles Salles memo-inoncology presented a 10-year update of the PRIMA trial, con- firming a progression-free survival (PFS) benefit for Dr. D. Heintel () Wilhelminenspital, Montleartstraße 37, 1160 Vienna, Austria daniel.heintel@wienkav.at 84 Update and clinical highlights presented at the 2017 American Society of Hematology Meeting K http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Update and clinical highlights presented at the 2017American Society of Hematology Meeting

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/update-and-clinical-highlights-presented-at-the-2017american-society-qIoGeGq6j0
Publisher
Springer Vienna
Copyright
Copyright © 2018 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
D.O.I.
10.1007/s12254-018-0417-x
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2018) 11:84 https://doi.org/10.1007/s12254-018-0417-x Update and clinical highlights presented at the 2017 American Society of Hematology Meeting Daniel Heintel Received: 2 May 2018 / Accepted: 22 May 2018 / Published online: 1 June 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 At the 2017 American Society of Hematology (ASH) rituximab maintenance following R-CHOP induction. meeting partly standards-changing data in the treat- The median PFS was 10.5 vs. 4 years (p < 0.0001). ment of hematological malignancies were presented. Also in mantle cell lymphoma, the superiority of More than 5000 scientific abstracts are submitted each rituximab maintenance was proven. year and more than 3000 abstracts are accepted for In fit patients with multiple myeloma, eligible for oral and poster presentations through an extensive autologous stem cell transplantation, new induction peer review process. In this issue of memo five hema- regimens showed high minimal residual disease neg- tologists summarized their personal highlights in their ativity rates. respective areas of expertise. Regarding CML interesting data regarding novel My personal highlight was the presentation of the TKIs or treatment duration of imatinib were pre- MURANO study. The clear superiority of a targeted sented. therapy changes practical behavior with immune- In the treatment of AML novel promising sub- chemotherapy having no place in second-line treat- stances enrich the spectrum of therapy choices which ment of chronic lymphocytic leukemia (CLL) any- also impressed the audience at the last ASH meeting. more. Moreover, the authors summarize important Conflict of interest D. Heintel receives honoraria from Abb- data about the combination of venetoclax and ibruti- vie, Celgene, Gilead, Janssen, MSD, Roche, Takeda. nib. In addition to CLL, reviews about important de- velopments in the treatment of indolent lymphoma, 7 For latest news from interna- multiple myeloma, CML, and AML are provided in this tional oncology congresses see: series. http://www.springermedizin.at/ Concerning indolent lymphoma, Dr. Gilles Salles memo-inoncology presented a 10-year update of the PRIMA trial, con- firming a progression-free survival (PFS) benefit for Dr. D. Heintel () Wilhelminenspital, Montleartstraße 37, 1160 Vienna, Austria daniel.heintel@wienkav.at 84 Update and clinical highlights presented at the 2017 American Society of Hematology Meeting K

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off